HBM Holdings-B (02142) experienced a significant surge in its stock price during the pre-market trading session on Thursday, with shares soaring 6.59% to reach HK$14.68. The stock saw a turnover of HK$8.02 million by the time of reporting, indicating strong investor interest.

The impressive rally comes on the heels of a strategic announcement made by the company on November 19. HBM Holdings-B revealed that its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd., has entered into a non-exclusive license agreement with pharmaceutical giant Pfizer. This collaboration aims to advance preclinical antibody discovery for multiple potential disease indications, signaling a significant step forward for the company's biotechnology endeavors.

Under the terms of the agreement, Pfizer will gain global access to Nona Biotechnology's proprietary HCAb platform, which is used for developing fully human heavy-chain-only antibodies. In return, Nona Biotechnology is set to receive an upfront payment and will be eligible for regulatory, clinical, and commercial milestone payments. Furthermore, the agreement opens doors for potential collaboration between Nona Biotechnology and Pfizer, leveraging the former's HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering. This partnership could potentially accelerate drug discovery processes and expand HBM Holdings-B's footprint in the biotechnology sector.